Peregrine Capital Management LLC Has $4.23 Million Stake in CeriBell, Inc. $CBLL

Peregrine Capital Management LLC grew its stake in CeriBell, Inc. (NASDAQ:CBLL) by 7.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 367,945 shares of the company’s stock after buying an additional 26,286 shares during the period. Peregrine Capital Management LLC owned approximately 1.00% of CeriBell worth $4,228,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in shares of CeriBell by 6,424.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after acquiring an additional 374,179 shares in the last quarter. TimesSquare Capital Management LLC grew its holdings in CeriBell by 48.5% during the second quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock valued at $14,927,000 after purchasing an additional 260,116 shares during the last quarter. Geode Capital Management LLC raised its position in shares of CeriBell by 55.4% in the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after purchasing an additional 159,698 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of CeriBell by 20,654.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 143,831 shares of the company’s stock worth $2,694,000 after buying an additional 143,138 shares during the period. Finally, Yu Fan grew its stake in CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after buying an additional 130,964 shares during the last quarter.

Insider Buying and Selling

In other CeriBell news, Director Rebecca B. Robertson sold 2,500 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $21.89, for a total transaction of $54,725.00. Following the completion of the transaction, the director directly owned 19,576 shares in the company, valued at $428,518.64. This represents a 11.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Xingjuan Chao sold 79,000 shares of CeriBell stock in a transaction on Monday, January 5th. The shares were sold at an average price of $21.27, for a total value of $1,680,330.00. Following the transaction, the chief executive officer directly owned 741,248 shares of the company’s stock, valued at approximately $15,766,344.96. The trade was a 9.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 350,212 shares of company stock worth $6,733,450. Insiders own 20.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CBLL. Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Raymond James Financial started coverage on CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective for the company. TD Cowen decreased their target price on CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Cowen reaffirmed a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. Finally, Canaccord Genuity Group upped their price target on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and an average target price of $24.67.

CeriBell Stock Up 1.1%

CBLL stock opened at $23.33 on Friday. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $26.04. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The company has a market cap of $865.54 million, a PE ratio of -15.45 and a beta of 1.02. The business’s 50-day simple moving average is $18.02 and its 200 day simple moving average is $15.08.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The firm had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. On average, research analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.